编码B细胞成熟抗原/CD3双特异性抗体的质粒DNA基因疗法用于治疗多发性骨髓瘤
本研究利用异种移植模型评估基因疗法递送靶向B细胞成熟抗原(BCMA)和CD3的双特异性抗体(BsAb)治疗多发性骨髓瘤(MM)的疗效。单次电穿孔增强肌内注射编码BCMA/CD3 BsAb的质粒DNA可显著延缓小鼠肿瘤生长,且观察到有限的毒性。研究表明,基于基因疗法递送BCMA/CD3 BsAb对MM治疗有效且安全。
要点
- 单次电穿孔增强肌内注射编码BCMA/CD3 BsAb的质粒DNA可显著延缓小鼠肿瘤生长。
- 治疗后可观察到有限的毒性。
- 基于基因疗法递送BCMA/CD3 BsAb对MM治疗有效且安全。
核心结论
- 基于基因疗法递送BCMA/CD3 BsAb对多发性骨髓瘤的治疗有效且安全。
研究设计与样本
- 研究采用异种移植模型评估基因疗法递送BCMA/CD3 BsAb的疗效。
主要发现
- 与溶媒对照组相比,单次电穿孔增强肌内注射编码BCMA/CD3 BsAb的质粒DNA可显著延缓小鼠肿瘤生长。
- 治疗后观察到有限的毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we evaluated the efficacy of this approach using a xenograft model. Tumour growth was significantly delayed in mice treated with single electroporation-enhanced intramuscular injection of plasmid DNA encoding BCMA/CD3 BsAb in contrast to the vehicle control-treated group. Limited toxicity was observed following treatment. This study demonstrates that the gene therapy-based approach for the delivery of BCMA/CD3 BsAb is effective and safe for the treatment of MM.
引用
- Peng F, Wang Y, Zhao J, et al. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma. Br J Haematol. 2022. PMID: 35594370. doi:10.1111/bjh.18230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。